Claudia G. S.
- Country
- Germany
- Department
- Vivantes Klinikum am Urban, Brustzentrum
Research Overview
- Phase III Randomized Study of Datopotamab Deruxtecan and Durvalumab in Neoadjuvant and Adjuvant Settings for Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer
- Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer
- Efficacy and Safety Evaluation of Ribociclib Plus Endocrine Therapy in HR-Positive, HER2-Negative Early Breast Cancer: A Phase IIIb Study
Data & Insights
Has run more than one trial at 41 of 233 partner sites.
Specializations
Breast Cancer Specialization
This investigator specializes in early-stage breast cancer treatment, with particular emphasis on hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) subtypes.
- Triple-negative breast cancer management
- HR+/HER2- breast cancer therapy
- Early-stage breast cancer treatment
Their research interests include innovative therapeutic approaches for low-risk breast cancer patients.
Therapeutic Innovation
The investigator focuses on personalized treatment strategies and novel therapeutic combinations, including targeted therapies and immunotherapy approaches.
- Immunotherapy combinations
- Targeted therapy applications
- Endocrine therapy optimization
Their work explores the integration of novel agents in breast cancer treatment protocols.
Clinical Outcomes
The investigator's research encompasses survival outcomes and treatment response assessment in early breast cancer.
- Disease-free survival analysis
- Treatment response evaluation
- Risk-stratified approaches
Their studies evaluate long-term clinical outcomes in breast cancer patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.